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Synopsis   
Breast cancer cells selected for high metastatic potential have elevated expression of MET and are 
hyper-responsive to macrophage-derived HGF, which promotes tumor cell extravasation and 
outgrowth. Blockade of macrophage-mediated HGF/MET signaling could have therapeutic potential 
for breast cancer.   
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Abstract   
Metastasis-associated macrophages (MAMs) promote persistent growth of breast cancer cells at 
the metastatic site and are, thus, an attractive therapeutic target to treat breast cancer metastasis, 
a leading cause of cancer-related death in women. However, the precise mechanisms behind 
MAM-mediated metastatic tumor outgrowth have not been fully elucidated. Using mouse models of 
metastatic breast cancer, we show that MAMs uniquely expressed hepatocyte growth factor (HGF) 
in metastatic tumors. We also demonstrated that a selected population of cancer cells with high 
metastatic potential (cancer cells that can establish metastatic tumors in mice with higher number 
and incidence than parental cells) had higher expression of HGF receptor, MNNG HOS 
transforming gene (MET) and were more responsive to HGF released from macrophages 
compared to the parental cells. Blockade of MET signaling in cancer cells suppressed metastatic 
tumor expansion, in part, through activation of natural killer (NK) cells. Results from this study 
suggest a new approach to prevent life-threatening metastatic tumor formation using blockade of 
MAM-induced MET signal activation in metastatic cancer cells.  
 
Introduction  
Breast cancer is a leading cause of cancer-related death in women, largely due to the metastasis 
in distant organs such as the bone and lung (1,2). Because 6-10% of breast cancer patients 
present with metastasis at diagnosis (3), novel therapies targeting metastatic tumor outgrowth are 
necessary (2). Attractive targets are tumor-associated macrophages (TAMs) in the primary and 
secondary sites (4). However, the roles of TAMs in metastasis are different in the primary and 
metastatic tumor microenvironment (5). Thus, investigation of TAM functions in metastatic sites is 
important to develop strategies to block metastatic tumor expansion. 
    In mouse models of breast cancer pulmonary metastasis, a distinct population of TAMs termed 
metastasis-associated macrophages (MAMs) promotes extravasation of circulating cancer cells, as 
well as subsequent survival and persistent growth at the metastatic site (6). However, the 
mechanisms by which MAMs promote metastatic tumor expansion are not fully understood, and, 
thus, targetable factors expressed by MAMs need to be identified.  
    Previous animal studies indicate that metastasis promotion by MAMs occurs through the 
secretion of growth factors. For example, MAMs secrete vascular endothelial growth factor (VEGF) 
that promotes extravasation of breast cancer cells by increasing vascular permeability, as well as 
subsequent tumor growth by activating VEGFR1 signaling in MAMs (7,8). It is, therefore, likely that 
MAM-derived secreted factors play key roles in the metastatic tumor outgrowth. Given that only a 
minor population of extravasated cancer cells can establish macroscopic metastatic tumors (9,10), 
 3 
we hypothesized that this metastatic population might have been selected to be more responsive 
to the MAM-derived factors and, thereby, able to expand more efficiently in the metastatic site. 
Here, we demonstrated that selected populations of mouse mammary and human breast cancer 
cells with high metastatic potential had higher expression of the hepatocyte growth factor (HGF) 
receptor, MNNG HOS transforming gene (MET), compared to low metastatic parental cells. This 
elevated expression resulted in an enhanced and prolonged MET signal activation in response to 
macrophage-derived HGF. We also showed that the activation of MET signaling in cancer cells 
promoted metastatic tumor outgrowth via suppression of tumor cell apoptosis induced by natural 
killer (NK) cells.  Our results suggest that blockade of macrophage-mediated MET signal activation 
could be a potential therapy to prevent metastatic tumor outgrowth of breast cancer.   
 
Materials and Methods  
Mice 
C57BL/6J, SCID (CB17-Prkdcscid/J), NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ), and human HGF 
knock-in (HGF-KI) SCID (Hgftm1.1(HGF)AveoPrkdcscid/J) mice were obtained from the Jackson 
Laboratory. Female SCID mice aged 4 weeks were irradiated with 9 Gy γ-rays and intravenously 
injected with 4x106 of bone marrow cells from HGF-KI or control SCID mice. The recipient mice 
were injected with LM2-4175 human breast caner cells after 6 weeks as described in ‘Metastasis 
model’ section. All studies were conducted in accordance with licensed permission from 
Institutional Animal Care & Use Committee of the Albert Einstein College of Medicine (#20120304) 
and the UK Home Office (P526C60B3). Sample size to generate significant results (P <0.05) were 
calculated with on-line software (Openepi). 
 
Healthy donor 
Peripheral blood was collected from 5 healthy donors. Blood samples kept on ice were processed 
to prepare monocyte-derived macrophages within one hour after collection. Informed consent was 
obtained from all donors included in this study. All study protocols were approved by the IRB of the 
Albert Einstein Medical College (Bronx, NY, USA).  
 
Cells 
E0771 mouse mammary adenocarcinoma cell line was kindly provided by Dr. E. Mihich (Rosewell 
Park Cancer Institute, NY) in 2010. The LM2-4175 cell line was kindly provided by Dr. J. Massagué 
(Memorial Sloan Kettering Cancer Center, NY) in 2007. MCF-7 and MDA-MB-231 human breast 
cancer cells and 3B-11 mouse endothelial cells were obtained from ATCC in 2011. These cells 
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were authenticated and certified by ATCC. All of these cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Invitrogen) including 10% v/v Fetal Bovine Serum (FBS, Sigma-Aldrich) 
and 1% v/v Penicillin/Streptomycin (Sigma-Aldrich). We do not culture these cell lines longer than 3 
months after thawing our stocks that were frozen at passage 3 after they were received. Mouse 
bone marrow-derived macrophages (BMMs) and human monocyte-derived macrophages (MDMs) 
were isolated as described previously (11,12), and cultured in alpha-Minimal Essential Medium 
(αMEM, Invitrogen) including 10% v/v FBS and recombinant human CSF1 (1x104 U/mL, Chiron 
Corporation). Conditioned medium was collected from macrophages cultured in αMEM including 
10% v/v FBS and recombinant human CSF1 (1x103 U/mL) for 24 hours. All cells were negative for 
mycoplasma.  
To obtain cancer cell subpopulations with high metastatic potential, we injected 1x106 of 
E0771 cells into the mammary fat pad or the tail vein of C57BL/6 mice and obtained the lung with 
metastatic tumors as described in ‘Metastasis models’. The tumor-bearing lungs were minced and 
incubated with dispase (Gibco) dissolved in Ca2+/Mg2+ free PBS (2.4U/mL) for 30 minutes at 37 ºC. 
The digested tissue was washed by PBS, and cultured in DMEM including 10% v/v FBS and 1% 
v/v Penicillin/Streptomycin. The in vivo selection was performed through 2 cycles. The 
metastasized cancer cells retrieved from spontaneous or experimental metastasis model were 
named E0771-HML2 or E0771-LG, respectively.  
E0771-parental, -HML2, and -LG cells were sub-cloned by limited dilution method. E0771-
LG cells were manipulated to express firefly luciferase and transfected with a TRIPZ inducible 
lentiviral shRNA vector (Dharmacon) including mouse Met shRNA (shMet#1; 5’-
GCCAATCTTGCTAAGCAAA-3' or shMet#2; 5’-GCTACTTATGTGAATGTAA-3’) or non-silencing 
shRNA (shControl; 5’-CTCGCTTGGGCGAGAGTAA-3’). These cells were cultured in DMEM 
supplemented with 10% v/v tetracycline-free FBS for their maintenance or with doxycycline (5 
μg/mL, Sigma) for shRNA induction up to 4 days.  
 
Metastasis models 
In a spontaneous metastasis model, 1x106 of E0771 cells were injected into the mammary fat pad 
of female C57BL/6J mice (7-weeks-old), and the primary tumor was surgically removed after 4 
weeks. Three weeks later, the lung was dissected and the existence of surface metastatic foci was 
confirmed under stereoscopic microscopy. The lung with metastatic tumor was used to retrieve 
cancer cells with higher metastatic potential (E0771-HML2) as described above.  
In experimental metastasis models, 1x106 of cancer cells were injected into the tail vein of 
female mice. E0771-parental, E0771-HML2, and E0771-LG cells expressing shRNA (shCont, 
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shMet#1, and shMet#2) were injected into syngeneic C57BL/6 mice (7-weeks-old). E0771-
LG:shMet#1 cells were also injected into SCID and NSG mice (7-weeks-old). LM2-4175 cells were 
injected into SCID mice that have received bone marrow cells from HGF-KI or control SCID mice 
as described above. To determine tumor load in the lung area, mice were injected with D-luciferin 
(GoldBio, 1.5 mg/20 g mouse) into the peritoneum and imaged using Photon Imager Optima 
(Biospace Lab) every 3-4 days. Photon counts (photon/second/cm2/sr) were quantified by M3 
Vision software (Biospace Lab). In some experiments using E0771-LG cells expressing shRNA, we 
gave doxycycline in the drinking water (SIGMA, 2 mg/mL in 5% w/v sucrose water) or vehicle from 
4 days after tumor injection to the experimental endpoint (day 10, 14 or 16 post-tumor injection). In 
some experiments, we injected blocking antibodies against mouse NK1.1 (PK136; BioXcell, 200 
μg/20 g mouse) into the peritoneum on days 4 and 7 after tumor injection.  
 
Spheroid invasion assay 
E0771-parental and E0771-HML2 mouse mammary tumor cells or MCF-7, MDA-MB-231, and 
LM2-4175 human breast cancer cells (5x104) were cultured on top of matrigel (2.5 mg/mL, BD 
Biosciences) in 35 mm glass bottom dishes, and incubated for 48 hours in αMEM including 10% 
v/v FBS with or without recombinant mouse/human HGF (10 ng/mL, Peprotech) or undiluted 
conditioned media (CM) from macrophages (mouse BMMs or human MDMs for mouse and human 
cancer cells, respectively). In some experiments, cells were incubated with 1 μM crizotinib (SIGMA) 
or a MET blocking antibody (20 μg/mL; R&D systems). We imaged randomly selected 5 fields with 
a Zeiss Axioskop II microscope at 10 x magnification, and enumerated spheres and invading cells 
using Fiji software (v1.49, National Institute Health).  
 
In vitro extravasation assay 
3B-11 mouse endothelial cells (2x104) were cultured on top of growth factor-reduced matrigel 
invasion chambers (BD Biosciences) for 48 hours, and BMMs (2x104) were loaded and attached to 
the bottom of the chambers. The chambers were then placed into a plate with DMEM including 
10% v/v FBS and CSF1 (1x104 U/mL). E0771 cells (2x104) labeled with CellTracker CMFDA 
(Molecular Probe) were loaded into the chambers with DMEM including 0.5% v/v FBS and 1x104 
U/mL CSF1. In some experiments, 1 μM crizotinib (SIGMA) was added into the culture. After 36 
hours, the chambers were fixed with 4% w/v paraformaldehyde, and cells on top were removed. 5 
randomly selected fields in each chamber were imaged by Olympus IX81 fluorescence microscope 




We extracted RNA from E0771-parental and E0771-HML2 cells using the RNeasy Micro/Mini Kit 
(Qiagen). RNA samples (15 μg) were hybridized on a GeneChip Mouse Genome 430 2.0 Array 
and scanned by GeneChip Scanner 3000 (Affymetrix). Datasets were annotated and normalized 
using the robust multichip average algorithm (rma) from the HuGene 1.0 transcript cluster 
database (Bioconductor). Genes with FDR ≤ 0.05 and log2FC ≥ +1.0 were considered differentially 
expressed. Among genes that were differentially expressed in E0771-HML2, trans-membrane 
receptor genes were identified as targets by Ingenuity Pathway Analysis software. Data is 
deposited into GEO (accession number: GSE138139). 
 
Kaplan-Meier plotter database analysis 
Using open access software KM Plotter (13), correlation between distant metastasis-free survival 
(DMFS) of breast cancer patients and expression of target genes (described above) was analyzed. 
A database was established using multiple microarray data sets downloaded from GEO, and 146 
patient data fitting to the selected parameters (Survival: DMFS, Intrinsic subtype: basal, and Grade: 
3) were analyzed. For each gene of interest, patients with grade III basal type breast cancer were 
separated into a high and low expression group based on the median value of the target mRNA 
expression, and Kaplan-Meier survival curves were plotted. A log-rank P < 0.01 was considered 
statistically significant. The gene ID used for the analysis are as follows: 203510_at (MET), 
202638_s_at (ICAM1), 215346_at (CD40), 238050_at (ANTXR2), 202803_s_at (ITGB2), 
201656_at (ITGA6), 1556582_at (PVR), 203650_at (PROCR), 210845_s_at (PLAUR), 206703_at 
(CHRNB1), 205718_at (ITGB7), 232317_at (PLXNA4), 218684_at (LRRC8D), 206211_at 
(ELAM1), 201743_at (CD14), 207072_at (IL18RAP), 204137_at (GPR137B), 209816_at (BCNS), 
205891_at (ADORA2B), 204116_at (IL2RG), 219761_at (CLEC1A), and 224392_s_at (OPN3).   
 
Real-time RT-PCR  
Total RNA was isolated from untreated cultured cells (BMM, 3B-11, E0771-parental, -HML2, and -
LG cells) using TRI Reagent (Sigma), and cDNA was synthesized from 2 μg of RNA using 
SuperScript III RT (Life Technologies). Real-time RT-PCR was performed using SYBR master mix 
(Invitrogen) with the following primers: Gapdh, 5’-AGAACATCATCCCTGCATCC-3’ and 5’-
CACATTGGGGGTAGGAACAC-3’; Hgf, 5’-ATGGGGAATGAGAAATGCAG-3’ and 5’-
CTCCCTCACATGGTCCTGAT-3’; Met, 5’-ATCATGGGACTTTGCTGGAC-3’ and 5’-
ACATTGGGATGGCTG AAGTC-3’. Expression of the target gene was normalized using Gapdh 
and reported as 2−ΔΔCT. 
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Western blotting  
E0771 cells cultured to 80% confluent were stimulated with recombinant mouse HGF (10 ng/mL, 
Peprotech) or undiluted BMM-conditioned medium for the indicated time in the presence of 300 nM 
crizotinib (SIGMA) or vehicle (DMSO, Sigma). Cells were lysed with RIPA Buffer including 1% v/v 
Halt Protease/Phosphatase Inhibitor (Thermo Scientific), separated by 4-15% w/v SDS gel 
electrophoresis (Bio-Rad) and transferred onto PVDF membrane (MILLIPORE). The membrane 
was blocked by Odyssey Blocking Buffer (LI-COR) overnight at 4°C, probed with a primary 
antibody (1:1000 dilution with blocking buffer) overnight at 4°C, and incubated with horseradish 
peroxidase-conjugated secondary antibody (1:2000 dilution with blocking buffer) for 1 h at room 
temperature after washing with Tris-Buffered Saline Tween-20. Signals were detected using Super 
Signal Femto (Thermo Scientific) and Odyssey Fc (LI-COR). The following antibodies from Cell 
Signaling Technology were used: Phospho-Met (#3077P), Met (#4560S), Phospho-Gab1 (#3234T), 
Gab1 (#3232T), β-actin (#3700S), Anti-Rabbit IgG (#7074P2), and Anti-mouse IgG (#7076P2). 
 
Flow cytometry  
The metastatic lungs were isolated at day 10 after tumor injection from C57BL/6 mice injected with 
E0771-LG:shMet#1 cells and treated with doxycycline or vehicle as described in ‘Metastasis 
models’. The lungs were minced by razor blade and incubated with the Lung Dissociation Kit 
(Miltenyi) at 37 ºC for 30 minutes. The single-cell suspensions were washed by PBS including 2% 
v/w bovine serum albumin (BSA, Sigma), filtered through a 40 μm cell strainer, and treated with 
RBC lysis buffer (Biolegend). 1x106 of cells were re-suspended in PBS including 2% v/w BSA were 
blocked with antibody for mouse CD16/CD32 (BD bioscience) on ice for 30 min, and then labeled 
on ice for 30 min using the following antibodies from Biolegend: anti-CD45 (30-F11), anti-F4/80 
(BM8), anti-Ly6G (1A8), anti-CD4 (GK1.5), anti-CD8 (53-6.7), anti-NK1.1 (PK136), anti-CD69 
(H1.2F3). Samples from the lung of mice without doxycycline treatment were used as a control.  
In order to compare the MET expression, human cancer cells (MCF-7, MDA-MB-231, and LM2-
4175) were harvested with 0.05% w/v Trypsin-EDTA (Gibco) and re-suspended in PBS including 
2% v/w BSA. 1x106 of cells were labeled with antibodies for human HGFR/c-MET (#95106, R&D) 
for 30 min on ice. Viability of stained cells was assessed by DAPI stain (Biolegend). The stained 
cells were detected using LSRII cytometer (BD Biosciences) and analyzed using Flowjo software 




To determine the size of metastatic tumors, the lungs were isolated at day 14 or 16 after tumor 
injection from C57BL/6 mice injected with E0771-LG cells expressing shRNA and treated with 
doxycycline as described in ‘Metastasis models’. The lungs were fixed with 4% w/v PFA overnight 
at 4 ºC, embedded into paraffin, and sectioned for H&E staining. All lobes were imaged using a 
Slide Scanner Zeiss Axio Scan Z.1 and analyzed using the Definiens Tissue Studio software to 
determine average nodule size.  
To detect HGF expression in immune cells, the metastatic lungs were isolated at day 10 
after tumor injection from C57BL/6 mice injected with E0771-LG cells, and directly embedded in 
OCT compound (Sakura Finetek). Frozen sections were fixed with cold acetone 5 minutes on ice, 
washed by cold PBS, and blocked with PBS including 3% v/v BSA and 10% v/v horse serum 
(Sigma). The sections were then incubated overnight at 4°C with antibodies to mouse HGF (15 
μg/mL, R&D) and antibodies (1:100) to Ly6G (1A8), CD3 (17A2), B220 (RA3-6B2) from Biolegend, 
F4/80 (CI:A3-1, Bio-Rad), or Fibroblast antibody (ER-TR7, Novus Biologicals) following 1 hour 
incubation with fluorescent secondary antibodies (1:500, Alexa555 anti-rat IgG and Alexa488 anti-
goat IgG from Molecular Probes) with DAPI (1:250, Invitrogen). Images were taken using Olympus 
BX61W1 Multiphoton FV1000 Microscope at 20 x and 60 x magnification.  The region with dense 
DAPI positive staining was outlined as the tumor area, which was confirmed by H&E staining of a 
serial section.  
 To detect apoptotic cancer cells, the lungs were isolated at day 10 after tumor injection from 
C57BL/6 mice injected with E0771-LG:shMet#1 and treated with doxycycline as described in 
‘Metastasis models’ and embedded in OCT compound.  
Sections were fixed and blocked as described above, and stained with antibodies (1:100) to ErbB2 
(ab16901, abcam) and cleaved caspase 3 (#9664L, Cell Signaling Technology) using the M.O.M. 
Detection Kit (Vector Labs) and Alexa555 anti-rabbit IgG. Images were taken using Olympus IX73 
fluorescence microscope at x10 magnification. The ErbB2+ region (tumor signal) and cleaved 
caspase 3+ region restricted to the tumor area (apoptosis signal) were quantified using Fiji software 
(v1.49, National Institute Health). The final apoptotic index was obtained by dividing the apoptosis 
signal value by the tumor signal value.  
 
MTT assay 
E0771-LG cells expressing shRNA (shCont, shMet#1, and shMet#2) were cultured with or without 
5 μg/mL doxycycline (Dox) for 3 days. 1x103 of the pre-treated cells were seeded into 96-well 
plates with phenol red free DMEM including 10% v/v FBS with or without 5 μg/mL doxycycline. 
After 3 days, cells were incubated with phenol red free DMEM including 10% v/v FBS and 1.2 mM 
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thiazolyl blue tetrazolium bromide (MTT, Sigma) for 4 hours, and then lysed by equal volume of 
water with 10 μM hydrochloride and 0.1% w/v SDS (Sigma) to determine absorbance 570 nm. 
To investigate effects of MET signal on in vitro cancer cell apoptosis, E0771-LG:shMet#1 
cells were cultured with or without 5 μg/mL doxycycline for 3 days, and 1x103 of these cells were 
seeded into 96-well plates with phenol red free DMEM including 10% v/v FBS and either 
recombinant mouse HGF (20 ng/mL), IFNγ (250 U/mL), TNFα (25 ng/mL), TRAIL (200 ng/mL) from 
Peprotech, or FAS activating antibody (1 μg /mL, JO2, BD Pharmingen). For a low attachment 
condition, 96-well plates were coated with Poly-2-hydroxethyl methacrylate (poly-HEMA, Sigma). 
These cells were cultured for 3 days, incubated with MTT, and lysed as described above. 
 
NK cell cytotoxicity assay  
NK cells were isolated from the spleen of normal C57BL/6 mice using EasySep Mouse NK Cell 
Isolation Kit (Stemcell Technologies) and re-suspended in αMEM including 10% v/v FBS. E0771-
LG:shMet#1 cancer cells were manipulated to express a red fluorescent protein (mKate) in the 
nucleus (E0771-LG:shMet#1_NLR) using NucLight Rapid Red Reagent (Essen Bioscience). In 
some experiment, E0771-LG:shMet#1_NLR were pre-incubated with 5 μg/mL doxycycline (Sigma) 
or PBS for 3 days and then stimulated with 20 ng/mL of recombinant mouse HGF (Peprotech) or 
PBS for 2 days in the presence or absence of 5 μg/mL doxycycline. In some experiments, 
conditioned medium was collected from E0771-LG:shMet#1_NLR cells cultured in αMEM including 
10% v/v FBS with or without 20 ng/mL HGF for 2 days. The pre-treated (or untreated) cancer cells 
were harvested with 0.05% w/v Trypsin-EDTA (Gibco) and re-suspended in αMEM including 10% 
v/v FBS. 1x103 target cancer cells and 4x103 effector NK cells were seeded in 96-well plates coated 
with basement membrane extract (Geltrex, Gibco), and co-cultured in αMEM including 10% v/v 
FBS (normal medium) or conditioned medium with 1000 U/mL IL-2 (Peprotech) and green 
fluorogenic caspase-3 substrate (NucView488, Biotium). The cultured cells were imaged by 
IncuCyte Zoom Live-Cell Analysis System (Essen Bioscience) at x10 magnification for 48 hours, 
and the number of apoptotic cancer cells (large red/green overlapping nuclei) was counted using 
the IncuCyte Zoom software (Essen).  
  
Statistical analysis 
All samples were collected independently and analyzed by at least two independent experiments. 
Data were expressed as mean ± SEM and analyzed by Student's t-test unless it is specified. In 
some cases, data were analyzed by Chi-square analysis. P <0.05 was considered significant. 




Cancer cells with high metastatic potential are responsive to macrophage-derived factors 
To obtain cancer cell subpopulations with high metastatic potential, we injected E0771 mouse 
mammary tumor cells (15) into the mammary fat pad of syngeneic C57BL/6 mice and retrieved the 
metastasized cells from the lung. We repeated this in vivo selection and established a second-
generation population (named HML2). This selected population developed pulmonary metastases 
with a significantly higher incidence and more lesions compared with parental cells (Fig. 1A-B). To 
compare responses to macrophages between HML2 and parental cells, we performed an in vitro 
extravasation assay (7,16). The migration of cancer cells through the endothelial monolayer was 
promoted by bone marrow-derived macrophages (BMMs) placed on the opposite side of the 
endothelial layer, and this macrophage-promoting extravasation was significantly enhanced in 
HML2 cells (Fig. 1C-D). We also performed a spheroid invasion assay that recapitulates the 
invasion of cancer cell clusters into solid tumors (17). Parental E0771 cells formed compact, 
multicellular tumor spheroids when cultured on high-density matrigel with unconditioned culture 
medium (DMEM with 10%v/v FBS), whereas the cells cultured in the medium conditioned with 
BMMs dissociated from the spheroids and invaded into the matrigel (Fig. 1E). The number of 
invading cells in the presence of BMM-conditioned medium was more than 10-fold higher in HML2 
(0.44±0.06) than in parental cells (0.03±0.001) (Fig. 1E-F). These data indicated that the 
population of E0771 cells with high metastatic potential was more responsive to macrophage-
derived secreted factors.  
 
MET activation by macrophage-derived HGF is enhanced in metastatic cancer cells 
We hypothesized that HML2 compared with parental cells have higher expression of receptors for 
macrophage-derived ligands that may transmit pro-metastatic signals to the cancer cells. To test 
this hypothesis, gene expression profiles between HML2 and parental cells were compared by 
microarray analysis. An unsupervised multi-dimensional scaling plot of all expressed genes 
showed clear separation of HML2 and parental cells (Supplementary Fig. S1A), and Ingenuity 
Pathway Analysis identified 19 candidate genes encoding trans-membrane receptors that had high 
expression (logFC>1.0, P<0.05) in HML2 compared to parental cells (Fig. 2A, Supplementary 
Fig. S1B). One of these genes encodes MET, an HGF receptor that can promote tumor metastasis 
in mice (18). Gene set enrichment analysis (GSEA) also suggests that MET pathway associated 
genes are differentially expressed by HML2 compared with parental cells (Supplementary Fig. 
S1C-D). Using a survival analysis tool (13), we further identified that high expression of MET, 
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ATRAB2, and PLAURI, but not others, significantly correlated with lower metastasis-free survival of 
breast cancer patients (Fig. 2B, Supplementary Fig. S2). Therefore, we hypothesized that 
enhanced expression of MET can make breast cancer cells more responsive to macrophages and, 
thereby, promote metastatic tumor expansion.  
    Consistent with the microarray data, we found significantly higher expression of Met mRNA (Fig. 
2C) and protein (Fig. 2D-E; total MET) in HML2 cells compared with parental cells. We also found 
that the ligand-dependent phosphorylation of MET, as well as its downstream target GRB2-
associated binder 1 (GAB1), were enhanced and sustained for longer periods in HML2 cells 
compared with parental cells (Fig. 2D-E). GAB1 activation was induced by conditioned-medium 
from BMM to a higher extent in HML2 than in parental cells, and this was significantly suppressed 
by Crizotinib, a small molecule MET inhibitor (Fig. 3A). These data indicated that a population of 
cancer cells with high metastatic potential (i.e., E0771-HML2 cells) expressed high MET that 
resulted in the enhancement of MET signaling in response to macrophage-derived HGF. We then 
investigated whether MET activation in HML2 contributed to their hyper-responsiveness to 
macrophages. In a spheroid invasion assay, invasion of HML2 cells enhanced by BMM-conditioned 
medium was completely suppressed by crizotinib or an MET neutralizing antibody (Fig. 3B). In an 
in vitro extravasation assay, BMM-enhanced extravasation of HML2 cells was also suppressed by 
crizotinib (Fig. 3C). Recombinant HGF alone significantly increased the number of extravasated 
cancer cells to a comparable level to that induced by BMMs, indicating that HGF is sufficient for 
cancer cell extravasation (Fig. 3C). These results highlighted the HGF/MET pathway as a pro-
metastatic signal that macrophages transmits to metastatic cancer cells. Supporting this 
conclusion, BMMs expressed higher Hgf mRNA compared with E0771-HML2 cancer cells or 3B11 
endothelial cells that were present in the in vitro extravasation assay (Fig. 3D). Using high-
resolution immunohistochemical detection, we further identified that HGF expression in E0771 
metastatic tumors was detected mainly in F4/80+ macrophages (i.e., MAMs), but not in Ly6G+ 
neutrophils, CD3+ T cells, or B220+ B cells (Fig. 3E, Supplementary Fig. S3A-B). Consistent with 
a previous report (19), HGF expression was not found in F4/80+ macrophages in the adjacent 
normal area that represented resident alveolar macrophages (Fig. 3F). These results showed that 
MAMs were the major source of HGF in the metastatic tumor microenvironment. Although cancer-
associated fibroblasts have been reported to produce HGF (20), we could not find ERTR7+ 
fibroblasts in the metastatic foci (Supplementary Fig. S3C). Collectively, these results indicated 
that breast cancer cells with high metastatic potential exhibited high expression of MET and were, 
thus, more responsive to HGF secreted by MAMs in the metastatic site.  
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Macrophage HGF activates MET signal in human breast cancer cells to promote metastasis  
Similar to mouse mammary tumor cells, a highly metastatic subpopulation of MDA-MB-231 human 
breast cancer cells (LM2-4175)(21) expressed significantly higher MET compared to their parental 
cells (Fig. 4A). We also found that in vitro invasion of LM2-4175 and MDA-MB-231 was promoted 
by human monocyte-derived macrophage (MDM)–conditioned medium to a significantly higher 
extent than in MCF-7 cells that expressed low levels of MET (Fig. 4A-B). The effect of MDM-
conditioned medium on tumor cell invasion was completely suppressed by Crizotinib (Fig. 4B) and 
was comparable with that of recombinant human HGF (Fig. 4C). These results indicated that 
metastatic human breast cancer cells expressed high MET, which enhanced their response to 
human macrophage-derived HGF.  
    It has been reported that a subpopulation of circulating tumor cells in breast cancer patients 
express high MET and that patients with high number of MET+ circulating cancer cells show more 
metastasis and shorter survival than patients with a low number of the cells (22). We, thus, 
hypothesized that MET activation by MAM-derived HGF was required for circulating breast cancer 
cells to establish metastatic tumors. To investigate this hypothesis, we injected LM2-4175 breast 
cancer cells expressing luciferase (21) into the tail vein of immunocompromised SCID mice, a 
means by which cancer cells are directly introduced into the circulation without being affected by 
early metastatic steps in the primary site. The recipient SCID mice were irradiated and transplanted 
with bone marrow cells from human HGF knock-in (HGF-KI) SCID mice in which mouse Hgf coding 
region is replaced by human HGF cDNA. Thereby, leukocytes in the bone marrow-transplanted 
(BMT:HGF-KI) mice secrete human HGF, whereas other host cells secrete mouse HGF. Mouse 
HGF binds to human MET with low affinity (23) and did not signal, as shown by the spheroid 
invasion assay where LM2-4175 human breast cancer cells did not respond to mouse HGF but 
showed a robust response to human HGF (Fig. 4C).  Therefore, in the metastatic site of BMT:HGF-
KI mice, the MET signal in the injected LM2-4175 cells would only be activated by HGF secreted 
from tumor-infiltrating leukocytes. In support of our hypothesis, the metastatic tumor loads in the 
lung were significantly higher in the BMT:HGF-KI mice compared with those in control mice without 
the human HGF gene (Fig. 4D-E). Because only MAMs expressed a significant amount of HGF 
among tumor-infiltrating leukocytes in mice (Fig. 3E), our results suggest that MAM-derived HGF 
promotes circulating human breast cancer cells to establish metastatic tumors.  
 
Reduced MET expression suppresses metastatic tumor outgrowth of breast cancer cells 
We further investigated whether MET signaling was required for the expansion of circulating tumor 
cells in the metastatic site. To this end and to indicate our data was not due to clonal variability in 
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the selected HML2 cell line, we used E0771-LG cells, another metastatic derivative of E0771 cells 
that reproducibly extravasate and establish micro-metastasis via MAM-mediated mechanisms by 
day 4 and develop into lethal macro-metastasis by day14 after intravenous injection (16,24). 
Expression of Met mRNA in E0771-LG cells was comparable with that in E0771-HML2 and 
significantly higher than E0771-parental cells (Fig. 5A). We manipulated E0771-LG cells to 
express luciferase and an inducible shRNA against Met mRNA (shMet). Expression of Met mRNA 
in cancer cells with shMet, but not control non-silencing shRNA (shCont), was decreased by 
doxycycline (Dox) treatment within 2 days without affecting their in vitro proliferation (Fig. 5B-C). 
We injected the E0771-LG:shMet or E0771-LG:shCont cells into C57BL/6 mice, and treated the 
animals with Dox from day 4 after tumor injection. As expected, the metastatic loads were not 
affected by the Dox treatment in mice with E0771-LG:shCont cells. In contrast, the Dox treatment 
significantly reduced pulmonary tumor burden by day 10 after tumor injection in mice that have 
received E0771-LG:shMet#1 cells (Fig. 5D). Although tumor load at day 14 in these mice was also 
lower than that in control mice, it was not statistically significant due to an outlier with significant 
tumor growth (Fig. 5E). At day 14, we isolated the lung and analyzed H&E sections (Fig. 5F) using 
a rigorous and accurate stereological method that reads out size of foci (i.e., tumor growth)(6). The 
Dox treatment also significantly reduced the average size of metastatic tumors established by 
E0771-LG:shMet#1 cells, whereas it did not affect the size of E0771-LG:shCont tumors (Fig. 5G). 
We found the reduction in metastatic tumor growth in mice injected with E0771-LG cells expressing 
another shMet construct (shMet#2), even though metastasis formation of this clone of cells was 
lower than that of E0771-LG:shMet#1 cells for unknown reasons (Fig. 5D-G). These results 
showed that breast cancer cells required MET signals for their metastatic tumor outgrowth. 
 
MET  prevents metastatic tumor cell apoptosis associated with NK cells  
Because metastatic foci established by E0771-LG:shMet cells in Dox-treated mice were sparse in 
contrast to tightly aggregated foci in control mice (Fig. 5F), we hypothesized that the MET signal 
might promote metastatic tumor outgrowth by preventing tumor cell apoptosis. We, thus, detected 
cleaved caspase-3, an apoptosis marker, in the metastatic tumor area indicated by ErbB2 
expression (Supplementary Fig. S3D). Although cleaved caspase-3 expression was very low in 
control tumors, it was significantly increased in tumors established by E0771-LG:shMet cells in 
Dox-treated mice (Fig. 6A-B), suggesting that disseminated cancer cells require MET signal to 
suppress apoptosis. To further investigate whether the HGF/Met signal transmits survival signals to 
cancer cells, we cultured E0771-LG:shMet cells with or without HGF and/or Dox under apoptotic 
conditions (depletion of serum, prevention of cell attachment, and incubation with recombinant 
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IFNγ, TNFα, TRAIL, and FAS activating antibody). Although these conditions, except for the 
incubation with TRAIL, significantly reduced viability of cancer cells, neither HGF stimulation nor 
reduced MET expression altered the extent of tumor cell death induced by these in vitro conditions 
(Supplementary Fig. S4).  
    We, thus, hypothesized that cancer cell apoptosis in the MET inhibited metastatic tumor was 
mediated by in vivo factors, possibly cytotoxic lymphocytes within the tumors. To investigate this 
hypothesis, we first evaluated the involvement of CD8+ T and natural killer (NK) cells in metastasis 
formation. We injected E0771-LG:shMet#1 cells intravenously into SCID mice (lack functional T 
cells) or NOD/SCID gamma (NSG) mice (lack mature T and NK cells). Although the metastatic 
tumor growth in the lung was significantly enhanced in SCID mice compared with immune 
competent C57BL/6 mice, it was further accelerated in NSG mice (Fig. 6C). NK cells induced 
apoptosis in E0771-LG cells in vitro (Supplementary Fig. S5). Together these results suggest 
possible roles of NK cells in suppressing metastasis formation. We thus investigated whether 
reduced MET expression in cancer cells increased accumulation of NK cells within the metastatic 
lung of C57BL/6 mice, but we did not find a significant difference in the number of NK cells in the 
lungs between MET expressing (Dox–) and inhibited (Dox+) tumors (Fig. 6D, Supplementary Fig. 
S6A). We then determined the activation status of these NK cells indicated by CD69 expression 
(25) and found that CD69 expression and the ratio of CD69+ cells to total tumor-infiltrating NK cells 
were significantly increased in MET-inhibited tumors compared to MET-expressing tumors (Fig. 
6E-F). These results suggest that inhibition of MET expression in cancer cells promotes NK cell 
activation in the metastatic site.  
To further investigate the contribution of NK cells to the growth suppression of MET-inhibited 
tumors, we injected a NK1.1 blocking antibody or control IgG at days 4 and 7 post-tumor injection 
into C57BL/6 mice with E0771-LG:shMet#1 tumors with or without Dox treatment from day 4 
(Supplementary Fig. S6B). The anti-NK1.1 treatments depleted NK cells in the lung 
(Supplementary Fig. S6C), and this treatment partially, but significantly, reversed the metastatic 
tumor load reduced by Dox treatment at day 10 after tumor injection (Fig. 6G), suggesting 
involvement of NK cells in metastasis suppression caused by MET inhibition. To investigate 
whether MET activation in cancer cells altered their susceptibility to NK cells, we cultured E0771-
LG:shMet cells with NK cells in the presence or absence of HGF and/or Dox, but neither MET 
knockdown nor HGF stimulation affected the NK cell induced tumor cell apoptosis in vitro 
(Supplementary Fig. S7A-B). Conditioned medium from E0771-LG:shMet cells cultured with HGF 
did not suppress NK cell cytotoxicity (Supplementary Fig. S7C-D), suggesting a minor contribution 
of MET activation in the secretion of NK cell suppressive molecules from cancer cells. Collectively, 
 15 
our data indicated that a population of cancer cells with high metastatic potential upregulate the 
expression of MET and thereby become more responsive to MAM-derived HGF, and that the 
enhanced HGF/MET signaling promotes metastatic tumor outgrowth by enhancing trans-
endothelial migration and suppression of NK cell functions (Figure 7).  
 
Discussion  
Previous reports showed that a subpopulation of circulating tumor cells in breast cancer patients 
has high MET expression, and this minor population can establish metastatic tumors in immune-
deficient mice (22). This data suggests that MET overexpression is advantageous for circulating 
breast cancer cells to form metastasis. However, very few studies have investigated the 
requirement of MET signals for cancer cells in the metastatic site. In this study, we identified that 
mouse mammary and human breast cancer cells, selected for high metastasis rates, expressed 
high MET and thereby, had enhanced responses to HGF delivered by MAMs. We also showed that 
MET overexpression in breast cancer cells was required for their trans-endothelial migration in vitro 
and persistent tumor growth in the lungs of mice. Knockdown of MET in human breast cancer cells 
also reduces their metastatic expansion in the bone of mice (26). These results indicated that 
breast cancer cells utilized HGF/MET signal for extravasation and metastatic tumor outgrowth in 
preferred sites for metastasis.  
    Although activating mutations and amplification of the MET gene can lead to constitutive MET 
activation, such genetic alterations are unusual in breast cancer (27). In a mouse model of breast 
cancer metastasis, blockade of DNA methyltransferase reduces MET expression in cancer cells 
and suppresses tumor growth in the bone (28). In human breast cancer cells, blockade of DNA 
methyltransferase increases miR-34-5p expression and concomitantly reduces MET expression 
(29). Because miR-34-a-5p expression negatively correlates with MET expression in human breast 
cancer bone metastases (29), it is possible that epigenetic modification of the MET gene induces 
MET overexpression in metastatic breast cancer cells. Several studies suggest that the MET 
overexpressing in cancer cells is activated via ligand-dependent mechanisms. For example, MET 
phosphorylation is scarcely found in a steady state but is increased by HGF stimulation in cultured 
breast cancer cells originating from patient-derived xenografts (30).  
MET and HGF are frequently co-expressed in human breast cancer, and high MET/HGF co-
expression associates with high tumor grade (27). Because 59% of MET overexpressing breast 
cancer expresses HGF in stromal cells (31), it is likely that MET signals in cancer cells is activated 
in a paracrine manner in a certain number of breast cancers. Several studies have shown that 
fibroblasts or neutrophils in squamous cell carcinoma or hepatocellular carcinoma secrete HGF 
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and promote invasion of cancer cells (32-34), which indicate these stromal cells as a source of 
HGF in the tumor microenvironment. However, in our models of breast cancer pulmonary 
metastasis, MAMs rather than neutrophils expressed high HGF and fibroblasts are rarely found in 
these metastatic tumors. These results suggest that HGF-producing cells differ between the 
primary and secondary site and between tumor types. In the current study, we demonstrated that 
macrophage-derived HGF promoted invasion and extravasation of high metastatic derivatives of 
breast cancer cells to a higher extent compared with low metastatic parental cancer cells in vitro, 
and that MET inhibition in cancer cells suppressed metastasis formation in mice. Using the same 
model, we have shown that metastasizing cancer cells directly interact with MAMs that accumulate 
in the metastatic site, and that inhibition of the MAM accumulation reduces metastasis formation 
(6,16). Collectively, our results suggest that the enhanced response to MAMs via an HGF/MET 
paracrine signal is one of the key characteristics of metastatic breast cancer cells, enabling them to 
extravasate and subsequently expand in metastatic sites. 
     We have previously reported that MAMs in the metastatic lung produce VEGF and promote 
extravasation of metastatic cancer cells through increasing vascular permeability (7). Here, we 
demonstrated that HGF from macrophages also promoted extravasation of cancer cells. HGF 
enhances in vitro endothelial adhesion and migration of MDA-MB-231 human breast cancer cells 
(35,36). However, HGF decreases rather than increases pulmonary endothelial cell permeability in 
vitro (37). Taken together, MAMs may promote three critical steps in extravasation via secretion of 
VEGF and HGF: (i) adhesion to endothelial cells, (ii) increasing vascular permeability, and (iii) 
migration through the vasculature wall (38). In future studies, it will be interesting to determine if 
MAM-derived HGF contributes to extravasation in different metastatic sites. 
    MAMs are also reported to promote metastatic tumor outgrowth via suppressing tumor cell 
apoptosis in the metastatic lung (6). Our results suggest that this process was also promoted via 
MET signaling. It is reported that MET activation in cancer cells can suppress anoikis and 
apoptosis induced by nutrient depletion, FAS, and TRAIL (39-42), conditions that circulating tumor 
cells may encounter during metastasis formation. In our in vitro model, however, HGF did not 
inhibit tumor cell death under these pro-apoptotic conditions. Instead, our in vivo data suggested 
that MET activation in cancer cells reduced NK cell-induced apoptosis. A study demonstrates that 
MET overexpression in renal cell cancer cells increases expression of PD-L1 (43), a ligand of the 
checkpoint receptor PD-1 that can suppress NK cell cytotoxicity (44). MET signaling prompts 
lymphoma cells to produce TGFβ (45) that can also suppress NK cell functions (46). These studies 
suggest that enhanced MET activation in cancer cells can reduce their susceptibility to NK cells via 
expression of molecules that directly suppress NK cell cytotoxicity. However, HGF stimulation did 
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not reduce apoptosis of E0771-LG mouse breast cancer cells induced by NK cells in vitro, 
suggesting the involvement of tumor microenvironment mediated by immune suppressor cells such 
as regulatory T cells and myeloid-derived suppressor cells (47).  
    Adoptive NK cell transfer has emerged as a novel cancer immunotherapy (48). However, 
efficacy of this therapy is limited by immunosuppressive tumor microenvironment. It is thus 
important to identify the mechanisms that modulate NK cell killing capability within the metastatic 
lesions to improve NK cell-mediated immunotherapy (49). Our results suggest that blockade of 
MAM-mediated HGF/MET signaling might be an attractive approach to improve NK cell transfer 
therapy. We have previously reported that the accumulation of MAMs in the metastatic site is 
promoted by cytokines and chemokines, such as colony-stimulating factor 1 (CSF1), CC-
chemokine ligand 2 (CCL2), and CCL3 (5-7,16). Therefore, targeting these cytokine/chemokine 
receptors in MAMs may reduce the local concentration of HGF in the metastatic tumors. Further 
investigation regarding synergistic therapeutic effects of antagonists against these 
cytokine/chemokine receptors in combination with MET inhibitors and NK cell therapy may lead to 
novel therapies for metastatic breast cancer.  
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Figure 1. Cancer cell invasion and extravasation induced by macrophage-derived factors 
are enhanced in a metastatic population of mouse mammary cancer cells. (A) The incidence 
of pulmonary metastasis formation in C57BL/6 mice intravenously injected with E0771-parental or 
their derivative HML2 cells (n=10/group). *P<0.01 versus parental, Chi-square analysis. (B) 
Average number of metastatic foci in the lungs of mice in A (n=10/group). *P<0.05 versus parental, 
Student’s t-test. (C) Number of cancer cells transmigrated through an endothelial monolayer in vitro 
in the presence or absence of bone marrow-derived macrophages (BMMs) and (D) fold increase in 
the number of transmigrated cancer cells with BMMs relative to that without BMMs (n=5). *P<0.05 
versus parental; #P<0.05 versus BMM–, Student’s t-test. (E) Representative morphology of cancer 
cell spheroids cultured with normal medium or BMM-conditioned medium (BMM-CM) for 48 hours. 
(F) Average number of invading cells in spheroids (n=5). *P<0.05 versus parental; #P<0.05 versus 
BMM–, Student’s t-test. Results are mean±SEM. 
 
Figure 2. Expression and activation of MET is increased in the metastatic population of 
mouse mammary cancer cells. (A) Genes encoding trans-membrane receptors in microarray 
data sets that were significantly upregulated (logFC >1, dotted red line, P<0.01) in HML2 compared 
with parental cells. The scale is exponential. (B) A Kaplan-Meier plot of metastasis-free survival of 
grade III basal type breast cancer patients with high and low expression of MET. In a database 
established using multiple microarray data sets downloaded from GEO, 146 patient data fitting to 
the selected parameters (Survival: DMFS, Intrinsic subtype: basal, and Grade: 3) were analyzed 
using KM Plotter. (C) Relative Met mRNA expression in parental and HML2 cells (n=3). *P<0.05 
versus parental, Student’s t test. (D) Representative images of western blots and (E) total and 
phosphorylated MET and GAB1 relative to β-actin in parental (Prnt) and HML2 cells stimulated with 
HGF (n=5) at the indicated time in hours (hr) after HGF stimulation. *P<0.05 versus time 0; #P<0.05 
versus parental, Student’s t test. Results are mean±SEM. 
 
Figure 3. Macrophage-derived HGF activates MET signaling in metastatic cancer cells. (A) 
Phospho-GAB1 relative to β-actin in parental and HML2 cells stimulated with normal medium or 
BMM-conditioned medium (BMM-CM) for 4 hours with MET inhibitor crizotinib (Crz) or vehicle 
(n=5). *P<0.05 versus parental; §P<0.05 versus normal; #P<0.01 versus vehicle, Student’s t test. 
(B) Average number of invading cells in E0771-HML2 spheroids cultured with normal medium or 
BMM-CM for 48 hours in the presence of Crizotinib, vehicle, blocking antibody  to MET (αMet), or 
control IgG (n=9). *P<0.01 versus normal; #P<0.01 versus vehicle/IgG controls, Student’s t test. (C) 
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Number of extravasated E0771-HML2 cells in vitro. Cancer cells were cultured for 36 hours in the 
presence or absence of BMMs with or without HGF and Crizotinib (n=6). *P<0.01 versus 
PBS:BMM–; #P<0.01 versus HGF, Student’s t test. (D) Relative Hgf mRNA expression in BMMs, 
E0771-HML2, and 3B11 endothelial cells (n=6). *P<0.01 versus BMMs, Student’s t test. (E,F) 
Expression of HGF and markers for macrophages (F4/80), neutrophils (Ly6G), T cells (CD3), or B 
cells (B220) in the lungs of animals with metastatic E0771 tumors (T), and macrophages in normal 
adjacent tissue (20 x magnification). Dotted line indicates a border of metastatic foci (n=3). Scale 
bar: 100 μm; Square indicates enlarged area at 60 x magnification. 
 
Figure 4. High MET expression in human breast cancer cells promotes pulmonary 
metastasis via leukocyte-derived HGF. (A) Average fluorescence intensity (geometric mean) of 
MET in the indicated cancer cell lines (n=3). *P<0.01 versus MCF7; #P<0.01 versus MDA-231, 
Student’s t test. (B) Average number of invading cells in spheroids of the indicated cell lines 
cultured with normal medium or conditioned medium from human monocyte-derived macrophage 
(MDM-CM) with or without Crizotinib (Crz). Cells were cultured for 48 hours (n=5). *P<0.05 versus 
normal; §P<0.01 versus MCF7:MDM-CM; ¶P<0.05 versus MDA231:MDM-CM; #P<0.05 versus 
MDM-CM, Student’s t test. (C) Average number of invading LM2-4175 cells cultured without (–) or 
with human (H) or mouse (M) HGF for 48 hours (n=5). *P < 0.05 versus HGF–, Student’s t test. (D) 
Representative images of mice at 28 days post-tumor injection and (E) average tumor load in the 
lungs (n=4/group). *P<0.05 versus BMT:SCID, Student’s t test.  No significant difference at day 0. 
Results are mean±SEM. 
 
Figure 5. Reduced expression of MET in mouse mammary cancer cells suppresses 
metastatic tumor expansion in the lung. (A) Relative Met mRNA expression in E0771-LG and 
HML2 cells compared with their parental (Prnt) cells (n=6). *P<0.01 versus parental, Student’s t 
test. (B) Relative Met mRNA expression in E0771-LG cells expressing tetracycline inducible 
shRNA against Met (shM#1, shM#2) or control non-silencing shRNA (shCont) cultured with 
doxycycline for 4 days (n=4). *P<0.05 versus day 0, Student’s t test. (C) Cell proliferation 
measured by MTT assay and expressed as a ratio to doxycycline (Dox) untreated E0771-
LG:shCont cells (n=7). ns; not significant. (D) Metastatic tumor load in the lungs of C57BL/6 mice 
injected with E0771-LG expressing inducible shRNA (shCont, shMet#1, shMet#2) and treated with 
or without Dox from day 4 after tumor injection (green arrows) to the endpoints (n=5/group). 
*P<0.05 versus Dox–, Student’s t test. (E) Bioluminescence images of mice shown in D at the 
experimental endpoint (day 14; shCont and shMet#1 or day 16; shMet#2). (F) Representative H&E 
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stained sections prepared from the lung at day 14 (shCont and shMet#1) or 16 (shMet#2) after 
tumor injection. Scale bar: 200 μm. (G) Average size of foci in the lungs at day 14 (shCont and 
shMet#1) or 16 (shMet#2) post-tumor injection (n=5). *P<0.05 versus Dox–, Student’s t test. 
Results are mean±SEM.  
 
Figure 6. Reduced MET expression increases tumor cell apoptosis partially through a NK 
cell mediated mechanism. (A) Expression of markers for cancer cells (ErbB2; green) and 
apoptosis (cleaved caspase 3; red) in the metastatic lungs of mice at day 10 post-tumor injection. 
Typical images of tumors at equivalent size are shown. Mice were injected with E0771-LG:shCont 
or E0771-LG:shMet#1 cells and treated with or without doxycycline (Dox) from day 4 to day 10 
post-tumor injection (n=3/group). Dotted line indicates a border of metastatic foci. Scale bar: 200 
μm. (B) Apoptotic index of the metastatic foci shown in A (n=3/group; total 30 tumors/group). 
*P<0.05 versus Dox–, Student’s t test. (C) Metastatic tumor load in the lungs of C57BL/6 (BL/6), 
SCID, and NSG mice injected with E0771-LG:shMet#1 cells (n=5/group). *P<0.05 versus BL/6, 
Student’s t test. (D) Number of NK cells in the metastatic lungs of mice at day 10 post-tumor 
injection. Mice were injected with E0771-LG:shMet#1 cells and treated with or without Dox from 
day 4 to day 10 post-tumor injection (n=5/group, two independent experiments). ns; not significant. 
(E) Representative histograms showing CD69 expression in NK cells detected in D. (F) Geometric 
mean fluorescence intensity (gMFI) of CD69 (left) and percentage of CD69+ cells (right) in NK cells 
detected in D (n=5/group, two independent experiments). *P < 0.01 versus Dox–, Student’s t test. 
(G) Metastatic tumor load in the lungs of mice at day 4 and 10 after tumor injection detected by 
bioluminescence imaging. Mice were treated with or without Dox from day 4 and were injected with 
a blocking antibody to mouse NK1.1 (αNK) or control IgG at days 4 and 7 after tumor injection 
(n=5/group). *P<0.05 versus Dox– IgG; #P<0.05 versus Dox+ IgG, Student’s t test. Results are 
means±SEM. 
 
Figure 7. Macrophage activation of MET signaling in cancer cells promotes extravasation 
and metastatic tumor outgrowth of metastatic breast cancer cells. Breast cancer cells with 
high metastatic potential express higher MET, a receptor for hepatocyte growth factor (HGF), than 
low metastatic cells. This expression results in enhanced and prolonged MET signal activation in 
response to macrophage-derived HGF. In the metastatic tumor, metastasis-associated 
macrophages (MAM) express HGF (red dotted arrows), and activation of MET signaling in cancer 
cells promotes their extravasation, as well as outgrowth, in part, through suppression of natural 
killer (NK) cell activity (blunted purple line) via affecting the immune suppressive tumor 
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microenvironment (dotted purple line). Gray and yellow lightning bolts represent limited and full NK 
cell cytotoxicity against cancer cells respectively.  
 
